FORA
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
CIN assigns Forian a Neutral rating in the Neutral band, with a mid-40s composite and low conviction. Fundamentals provide the largest contribution, scoring in the low 50s, supported primarily by a gross-margin subscore near 80 and a cash-runway subscore above 60. Regulatory ranks second at just under 50, as a neutral jurisdiction posture and a strong enforcement subscore offset weak filing cadence. Market contribution sits near 40 because no institutional quote is available, while editorial contribution trails near 30 due to absent newsroom and brief activity. The pillar mix supports neither a premium stance nor a decisive negative call.
Licensed fundamentals data show revenue contracting by roughly 3% year over year. Gross margin remains close to 47%, representing the clearest operating strength, but the operating loss exceeds half of revenue and prevents that margin from producing viable earnings. EBITDA remains negative at approximately $5.6 million, while the bottom-line loss stands near $5.1 million. The cash-burn ratio is a little above 8%, and the stated financial condition remains stretched. Primary regulatory filings show no recorded filing date and no identified regulatory events across either the latest 90-day or 180-day periods. The cadence subscore near 25 constrains regulatory confidence despite no enforcement hits and an enforcement subscore around 80. Institutional pricing feeds provide no current quote, while CIN newsroom coverage contains no recent newsroom or brief hits.
The forward catalyst rests squarely on fundamentals, the strongest pillar. Forian’s gross-margin profile demonstrates underlying economic value, but a re-rating requires evidence that this margin base can translate into lower operating losses and renewed top-line expansion. Stable gross margin near the high-40% area, paired with tighter cost absorption, would lift the weakest components within the fundamentals pillar and strengthen the composite from its current Neutral position. More consistent primary regulatory filings would improve transparency, although filing cadence remains secondary to operating execution. The single most important signal to watch is sustained operating-margin improvement generated from the existing gross-margin base.
- SEC CIK
- 0001829280
- Website
- Company website
- Market cap
- $67.8M
- Enterprise value
- $36.3M
- PEG ratio
- 0.94
- Price to book
- 2.28
- Price to sales
- 2.26
- EV / EBITDA
- 20.05
- Revenue (TTM)
- $30.1M
- Gross profit (TTM)
- $14.2M
- EBITDA
- $-5.6M
- Operating margin
- -50.9%
- Profit margin
- -17.0%
- Rev growth YoY
- -2.9%
- Return on equity
- -17.9%
- Return on assets
- -8.4%
- EPS (TTM)
- $-0.09
- EPS est. current year
- $0.09
- Wall St. target price
- $2.10
- Shares outstanding
- 31.2M
- Insider ownership
- 51.8%
- Institutional ownership
- 14.9%
- Beta
- 0.93
- Full-time employees
- 50
- GICS sector
- Healthcare
- GICS industry
- Health Information Services
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for FORA (FORA)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for FORA (FORA), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for FORA are maintained by Cannabis Investor News and refreshed throughout the trading day.